Status:
WITHDRAWN
D-cycloserine Augmented Treatment for Youth With Tic Disorders
Lead Sponsor:
Johns Hopkins University
Conditions:
Tourette Syndrome
Eligibility:
All Genders
8-17 years
Phase:
EARLY_PHASE1
Brief Summary
This pilot study aims evaluate the feasibility and initial efficacy of behavior therapy augmented by d-cycloserine (DCS) compared to behavior therapy augmented by placebo. After an initial assessment ...
Detailed Description
Tourette's Disorder and Persistent Tic Disorders (collectively referred to as TD) are characterized by the presence of motor and/or vocal tics. For many youth with TD, the severity of tics results in ...
Eligibility Criteria
Inclusion
- 8-17 years
- Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for Tourette's Disorder, Persistent Motor Tic Disorder, or Persistent Vocal Tic Disorder
- Have moderate tic severity or greater as evidenced by a Yale Global Tic Severity Scale (YGTSS) total score greater than 13 (\>9 for children with motor or vocal tics only)
- Be fluent in English
Exclusion
- Current diagnosis of substance abuse/dependence
- Lifetime diagnosis of autism spectrum disorder, mania or psychosis
- History of a seizure disorder, kidney disease, or liver disease
- Four or more previous sessions of behavior therapy
Key Trial Info
Start Date :
April 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04357951
Start Date
April 15 2023
End Date
September 1 2024
Last Update
April 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21205